OPR - Delayed Quote • USD KPTI May 2024 2.000 put (KPTI240517P00002000) Follow 0.6000 0.0000 (0.00%) At close: March 28 at 3:51 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for KPTI240517P00002000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: KPTI Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ... Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript Q4 2023 Karyopharm Therapeutics Inc Earnings Call Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress 7 Biotech Penny Stocks on the Verge of Clinical Trial Victory Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
